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SHORT COMMUNICATION
Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours
of the ovary - a new therapeutic approach?
S.T.A. Malik & M.L. Slevin
ICRF Department ofMedical Oncology, St. Bartholomew's and Homerton Hospitals, London, UK.
Granulosa cell tumours of the ovary comprise approximately
3-5% of all ovarian neoplasms (Williams, 1985). They are
sometimes associated with secretion of oestrogens, and less
commonly androgens and progestagens. These tumours often
have a protracted history and can recur many years after
excision of the original tumour. Treatment of metastatic
tumour generally involves radiotherapy to achieve disease
control at metastatic sites (Simmons & Sciarra, 1967) or
chemotherapy (Camlibel & Caputo, 1983). Extraabdominal
spread is one of the factors associated with a poor prognosis
(Fox et al., 1975). We document here the response of metas-
tatic granulosa cell tumour of the ovary in two patients to
therapy to oral medroxyprogesterone acetate (MPA).
Case 1
A 56 year old nulliparous woman presented with post meno-
pausal bleeding and underwent a total abdominal hysterec-
tomy and bilateral salpingo-oophorectomy. Histology of the
left ovary revealed a malignant granulosa cell tumour. Nine
years later she presented with a haemorrhagic metastatic left
iliac tumour and liver metastases, and was treated with six
courses of Carboplatin with no response. The disease re-
mained static for another 12 months, when the patient
became symptomatic due to progressive liver metastases. She
received a course of radiotherapy to the liver (1000 cGy).
Two months later, a 6 x 4 cm palpable mass was noted in the
right iliac fossa. This was confirmed by ultrasound, which
also revealed additional liver metastases. The patient was
commenced on MPA (100 mg tds). A month later the patient
felt much better, and clinical examination suggested a de-
crease in the size of the RIF mass. This was impalpable 4
months after MPA started. An ultrasound examination
confirmed this, and also showed that a large liver metastasis
had decreased in size from 10.2 x 13.2 x 10.1 cm to
6 x 3.5 x 5 cm. Two additional liver metastases present at
the time of starting MPA, had disappeared. The patient
remains well, on MPA, over 2 years after starting therapy, in
stable partial remission.
Case 2
A 46 year old multiparous woman had a diagnosis of malig-
nant granulosa cell tumour, and underwent a total abdom-
inal hysterectomy and bilateral salpingo-oophorectomy. Six
years later she presented with bilateral ureteric and bowel
obstruction due to widespread pelvic and intraabdominal
metastases. She responded to chemotherapy (six courses of
Carboplatin), but relapsed a year later and again there was a
partial response to Carboplatin. Further disease progression
was documented 12 months later, and this time the disease
did not respond to either Carboplatin or adriamycin. An
ultrasound examination revealed a large pelvic tumour and
liver metastases. The patient was commenced on MPA
(100 mg tds). Two months later ultrasound and clinical exam-
ination revealed decrease in the size of the pelvic mass, which
was less than the 50% needed to fulfill the criteria for an
objective response, and progression was documented on ultra-
sound examination 2 months later. The dose of MPA was
increased to 200 mg tds, and further response was docu-
mented a month later (again less than 50%), and the disease
progressed within 3 months. At this stage, the patient had a
mass palpable 3 cm above the symphysis pubis. The dose of
MPA was increased to 300 mg tds, and the patient evaluated
a month later. Clinically the suprapubic mass was impal-
pable, and pelvic ultrasound confirmed that its dimensions
had decreased from 19 x 13 x 11 cm, to 15 x 10 x 10cm (a
volume decrease of 44%). Although the objective measure-
ments of decrease in the size of the tumour do not fulfill the
criteria for a partial response (>50% decrease in size) to
MPA, the patient continues to be well in stable remission 9
months on, and the pelvic tumour, has shown increasing
calcification. On clinical assessment this patient appears to
have responded to MPA.
Discussion
The management of metastatic granulosa cell tumours con-
sists of radiotherapy to selected sites and chemotherapy.
There are a few studies reporting the response of these
tumours to chemotherapeutic agents. The treatment of a
total of 38 patients with single agent and combination
chemotherapy was reviewed by Camlibel and Caputo (1983).
Response rates (CR and PR) in small numbers of patients
were 25% for chlorambucil and cyclophosphamide as single
agents. Adriamycin as a single agent led to complete res-
ponses in two out of three patients. The authors concluded
that the use of combination chemotherapy with cis-platimum,
adriamycin, and cyclophosphamide was their regimen of
choice in advanced cases on the basis of responses obtained
in two patients. There has not been any extensive reported
experience of single agent cis-platinum therapy in granulosa
cell tumours. Both the patients reported here were initially
treated with carboplatin. No response was seen in the first
patient, but a partial response was obtained in the second
patient with the initial course ofcarboplatin, and again when
the disease progressed. The natural history of granulosa cell
tumours and the small number of patients available have not
allowed any judgement of the impact of chemotherapy
or radiotherapy on the survival of patients with advanced
disease in randomised trials.
The cases reported here are the first to describe the un-
equivocal regression of granulosa cell tumours of the ovary
following oral progestagen therapy. Although the presence of
progesterone receptors was not established in the tumours of
the two patients reported in this paper, progesterone recep-
tors have been demonstrated in granulosa cell tumours by
others (Kurman et al., 1979; Galli et al., 1981; Meyer et al.,
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1982; Schwartz et al., 1983). Kurman et al. (1979) were able
to demonstrate progesterone receptors in six out of 11
granulosa cell tumours by immunohistochemical techniques.
Galli et al. (1981), and Meyer et al. (1982), also showed the
presence ofprogesterone receptors in a total of three tumours
studied, and suggested that therapy with progestagens may
be effective in their treatment. Schwartz et al. (1983) were
able to demonstrate progesterone receptors in two out of
three tumours studied, and reported stabilisation of disease
in one patient with progestagen therapy. Young et al. (1982)
showed specific binding of tritiated MPA to a cytosolic pro-
gesterone receptor in a granulosa cell tumour of the ovary.
The cases reported here demonstrate that MPA can induce
tumour regression in advanced cases of granulosa cell
tumours that have become resistant to first-line combination
chemotherapy. A point of interest was the possible dose-
response relationship noted in one of the patients, suggesting
that dose escalation should be considered in patients not
responding initially to MPA at a dose of 100 mg three times
a day. MPA should be considered as a possible therapy in
patients with granulosa cell tumours ofthe ovary after failure
of first-line chemotherapy, or indeed as a potential first-line
therapy in patients unsuitable for chemotherapy.
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